Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
The Pharma Data
MAY 8, 2021
Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.
Let's personalize your content